PTGS2 and Alzheimer disease: Administration of N-acetyl sphingosine (N-AS), an intermediate generated by SphK1, further enhanced acetyl-S565 COX2 levels and SPMs secretion (e.g., 15R-LxA4, RvE1, RvD1), thereby ameliorating AD pathologies.